Showing results (31-40 of 86) with videos related to
Sort By:
Pageof 9
Leukemia Research|October 12, 2007
Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AMLAnjali S Advani, Cristina Rodriguez, Tao Jin, et al.British Journal of Haematology|December 15, 2018
Lenalidomide-based response-adapted therapy for older adults without high risk myelomaRachid Baz, Syeda Mahrukh Hussnain Naqvi, Jae-Hoon Lee, et al.Leukemia & Lymphoma|April 7, 2010
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysisRachid Baz, Mehul Patel, Elizabeth Finley-Oliver, et al.Mayo Clinic Proceedings|July 14, 2006
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myelomaMohamad A Hussein, Rachid Baz, Gordan Srkalovic, et al.Clinical Lymphoma, Myeloma & Leukemia|May 3, 2022
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective StudyYumeng Zhang, Lauren Duncanson, Jason Brayer, et al.Journal of Hematology & Oncology|August 26, 2016
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJoel G Turner, Jana L Dawson, Steven Grant, et al.Leukemia Research|July 2, 2013
Sequence of novel agents in multiple myeloma: an instrumental variable analysisRachid Baz, Branko Miladinovic, Amila Patel, et al.Mayo Clinic Proceedings|December 14, 2005
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myelomaRachid Baz, Liang Li, Kandice Kottke-Marchant, et al.Ebiomedicine|April 9, 2020
A pharmacodynamic model of clinical synergy in multiple myelomaPraneeth Sudalagunta, Maria C Silva, Rafael R Canevarolo, et al.Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.Pageof 9